BeiGene has announced their Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA (zanubrutinib) has been approved by Swissmedic to treat adult patients with Waldenström’s macroglobulinemia (WM). WM is a rare B-cell lymphoma that is primarily found in bone marrow and usually affects older adults. BRUKINSA was discovered by BeiGene scientists and has differentiated pharmacokinetics compared to other approved BTK inhibitors. It was designed to provide complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity, and has demonstrated its ability to inhibit the rapid growth of malignant B cells within numerous disease relevant tissues. BeiGene is a global biopharmaceutical company that specializes in developing affordable medication for cancer treatment. Its goal is to build an organization that is recognized for its impact in cancer research and drug development.

Read more here.

More on: